AU2002213424A1 - Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter - Google Patents

Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter

Info

Publication number
AU2002213424A1
AU2002213424A1 AU2002213424A AU1342402A AU2002213424A1 AU 2002213424 A1 AU2002213424 A1 AU 2002213424A1 AU 2002213424 A AU2002213424 A AU 2002213424A AU 1342402 A AU1342402 A AU 1342402A AU 2002213424 A1 AU2002213424 A1 AU 2002213424A1
Authority
AU
Australia
Prior art keywords
inhibition
treatment
diabetes mellitus
mitochondrial calcium
sodium antiporter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213424A
Inventor
Christen M. Anderson
Robert E. Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Mitokor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor Inc filed Critical Mitokor Inc
Publication of AU2002213424A1 publication Critical patent/AU2002213424A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2002213424A 2000-09-20 2001-09-20 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter Abandoned AU2002213424A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23392500P 2000-09-20 2000-09-20
US60/233,925 2000-09-20
US25600100P 2000-12-15 2000-12-15
US60/256,001 2000-12-15
PCT/US2001/042275 WO2002024204A2 (en) 2000-09-20 2001-09-20 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter

Publications (1)

Publication Number Publication Date
AU2002213424A1 true AU2002213424A1 (en) 2002-04-02

Family

ID=26927377

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213424A Abandoned AU2002213424A1 (en) 2000-09-20 2001-09-20 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter

Country Status (6)

Country Link
US (1) US20020082193A1 (en)
EP (1) EP1322314A2 (en)
JP (1) JP2005503993A (en)
AU (1) AU2002213424A1 (en)
CA (1) CA2422671A1 (en)
WO (1) WO2002024204A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526024A (en) 2002-02-08 2005-09-02 スミスクライン ビーチャム コーポレーション Compounds for inhibiting insulin secretion and methods related thereto
WO2003068263A1 (en) * 2002-02-15 2003-08-21 Taisho Pharmaceutical Co.,Ltd. Remedy for hypertension
US20060014175A1 (en) * 2004-05-17 2006-01-19 Imad Naasani Functionalized fluorescent nanocrystal detection system
US8791079B2 (en) 2009-03-11 2014-07-29 The Johns Hopkins University Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mNCE)
CN108514557B (en) * 2018-07-04 2019-04-12 南京市儿童医院 Application of the rotenone in pancreas islet protection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5930776A (en) * 1993-11-01 1999-07-27 The Golden 1 Credit Union Lender direct credit evaluation and loan processing system
US5758324A (en) * 1995-12-15 1998-05-26 Hartman; Richard L. Resume storage and retrieval system
US6026374A (en) * 1996-05-30 2000-02-15 International Business Machines Corporation System and method for generating trusted descriptions of information products
US5864871A (en) * 1996-06-04 1999-01-26 Multex Systems Information delivery system and method including on-line entitlements
US5884270A (en) * 1996-09-06 1999-03-16 Walker Asset Management Limited Partnership Method and system for facilitating an employment search incorporating user-controlled anonymous communications
US5978768A (en) * 1997-05-08 1999-11-02 Mcgovern; Robert J. Computerized job search system and method for posting and searching job openings via a computer network
US6064980A (en) * 1998-03-17 2000-05-16 Amazon.Com, Inc. System and methods for collaborative recommendations
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
WO2001034833A2 (en) * 1999-11-10 2001-05-17 Mitokor Regulating endogenous inhibitor at atp synthase

Also Published As

Publication number Publication date
WO2002024204A2 (en) 2002-03-28
US20020082193A1 (en) 2002-06-27
WO2002024204A3 (en) 2002-08-22
JP2005503993A (en) 2005-02-10
EP1322314A2 (en) 2003-07-02
CA2422671A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
NZ523557A (en) Calcium salt of valsartan
AU2002215223A1 (en) Preventive or therapeutic medicines for diabetes containing fused-heterocycle compounds or their salts
AU2003244398A1 (en) Engineering absorption of therapeutic compounds via colonic transporters
AU2002332513A1 (en) Calcium hypochlorite of reduced reactivity
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2001292480A1 (en) Novel pyridazine compounds for the treatment of diabetes
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003256650A1 (en) Substituted thiophene carboxamide compounds for the treatment of inflammation
AU2001285325A1 (en) Use of threo-methylphenidate compounds to enhance memory
AU2002330095A1 (en) Flavonoids for treatment of diabetes
AU2002213424A1 (en) Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter
AU2003217214A1 (en) The use of sulfonated compounds as a barrier contraceptive
AU2002303132A1 (en) Inhibition of toxoplasma gondii) replication by pyridinylimidazoles
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU2002322728A1 (en) Solid phase syntheis of salts of organic acid
AU2002327440A1 (en) Treatment of type i diabetes
IT1320192B1 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PSORIASIS.
AU2001258598A1 (en) Use of metal compounds to treat gastrointestinal infections
AU2003255758A1 (en) Improvements relating to water treatment
AU6478900A (en) Novel use of angelan from angelica gigas for treating diabetes mellitus
AU2001286052A1 (en) Improvements relating to water treatment
AU2003229181A1 (en) Stable dosage forms comprising atorvastatin calcium
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2002367305A1 (en) Foot orthosis
AU2003252185A1 (en) Topical composition for the treatment of scar tissue